• Product name

    Anti-GATA4 (phospho S105) antibody
    See all GATA4 primary antibodies
  • Description

    Rabbit polyclonal to GATA4 (phospho S105)
  • Host species

  • Tested applications

    Suitable for: ICC/IF, EMSA, IHC-Fr, WBmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Dog
    Predicted to work with: Chicken, Human
  • Immunogen

    Synthetic peptide (Human) derived from a region of GATA 4 that contains serine 105.

  • Positive control

    • Phenylephrine (PE)-stimulated rat cardiomyocytes, transfected with mouse GATA 4.



Our Abpromise guarantee covers the use of ab5245 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration. PubMed: 19546173
EMSA Use at an assay dependent concentration.
IHC-Fr Use at an assay dependent concentration. PubMed: 22919071
WB Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 45 kDa (predicted molecular weight: 46 kDa).


  • Function

    Transcriptional activator that binds to the consensus sequence 5'-AGATAG-3' and plays a key role in cardiac development (PubMed:24000169). Involved in bone morphogenetic protein (BMP)-mediated induction of cardiac-specific gene expression (By similarity). Binds to BMP response element (BMPRE) DNA sequences within cardiac activating regions (By similarity). Acts as a transcriptional activator of ANF in cooperation with NKX2-5 (By similarity). Promotes cardiac myocyte enlargement (PubMed:20081228). Required during testicular development (PubMed:21220346). May play a role in sphingolipid signaling by regulating the expression of sphingosine-1-phosphate degrading enzyme, spingosine-1-phosphate lyase (PubMed:15734735).
  • Involvement in disease

    Atrial septal defect 2
    Ventricular septal defect 1
    Tetralogy of Fallot
    Atrioventricular septal defect 4
    Testicular anomalies with or without congenital heart disease
    GATA4 mutations can predispose to dilated cardiomyopathy (CMD), a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
  • Sequence similarities

    Contains 2 GATA-type zinc fingers.
  • Post-translational

    Methylation at Lys-300 attenuates transcriptional activity.
  • Cellular localization

  • Information by UniProt
  • Database links

  • Alternative names

    • ASD2 antibody
    • GATA 4 antibody
    • GATA binding protein 4 antibody
    • GATA-binding factor 4 antibody
    • gata4 antibody
    • GATA4_HUMAN antibody
    • MGC126629 antibody
    • Transcription factor GATA 4 antibody
    • Transcription factor GATA-4 antibody
    • Transcription factor GATA4 antibody
    • VSD1 antibody
    see all


  • Extracts prepared from cardiomyocytes overexpressing wild-type GATA-4 (1-4 from left to right) stimulated with phenylephrine (PE) for 24 hours were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4°C, then were incubated with 0.35 µg/mL ab5245 for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1), the non-phosphopeptide corresponding to the immunogen (2), a generic phosphoserine-containing peptide (3), or, the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to GATA-4 [pS105] blocks the antibody signal, and that the S105A mutant does not react, thereby demonstrating the specificity of the antibody.
    Extracts prepared from cardiomyocytes o


This product has been referenced in:

  • Li T  et al. The status of MAPK cascades contributes to the induction and activation of Gata4 and Nkx2.5 during the stepwise process of cardiac differentiation. Cell Signal 54:17-26 (2019). Read more (PubMed: 30471465) »
  • Xu H  et al. GATA-4 regulates neuronal apoptosis after intracerebral hemorrhage via the NF-?B/Bax/Caspase-3 pathway both in vivo and in vitro. Exp Neurol 315:21-31 (2019). Read more (PubMed: 30710529) »
See all 15 Publications for this product

Customer reviews and Q&As

1-3 of 3 Abreviews or Q&A

Immunocytochemistry/ Immunofluorescence
Human Cell (Vascular smooth muscle cell)
Yes - NP40
Vascular smooth muscle cell
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 24°C

Abcam user community

Verified customer

Submitted Aug 04 2017

Western blot
Human Cell lysate - whole cell (pancreatic cancer)
Gel Running Conditions
Reduced Denaturing
Loading amount
30 µg
pancreatic cancer
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C

Abcam user community

Verified customer

Submitted Feb 09 2016


Thank you for your protocol details, I'm very sorry to hear you are experiencing problems with ab5245 and would like to recommend the following advice: 1) please make sure that the protein is in its phosphorylated form: do you have a stimulation paradigm to induce the phosphorylation? Do you know if basal phosphorylation levels in your samples are high? 2)the wrong band sizes may be due to the dephosphorylation of the protein due to the absence of phosphatase inhibitors in the lysis buffer. Please use the following buffer: Cell Lysis Buffer Formulation: 10 mM Tris, pH 7.4 100 mM NaCl 1 mM EDTA 1 mM EGTA 1 mM NaF 20 mM Na4P2O7 2 mM Na3VO4 0.1% SDS 0.5% sodium deoxycholate 1% Triton-X 100 10% glycerol 1 mM PMSF (made from a 0.3 M stock in DMSO) or 1 mM AEBSF (water soluble version of PMSF) 60 µg/mL aprotinin 10 µg/mL leupeptin 1 µg/mL pepstatin (alternatively, protease inhibitor cocktail ) 3) the membrane is not blocked sufficiently/adequately. Do not use milk to block membranes probed for phosphorylated proteins as milk contains casein which is a phosphoprotein (the antibody will bind the milk on all the membrane. We recommend to block the membrane in 5% BSA overnight at 4oC and to incubate the blocked blot with primary antibody at a concentration of 0.1-1.0 µg/mL in Tris buffered saline supplemented with 1% BSA and 0.1% Tween 20 for 2 hours at room temperature. Please also check that a "no primary" control with just your secondary antibody does not give a signal, which would indicate the problem is also due to the secondary. I hope this information will help you, please let me know if you need further advise (a full protocol is available on the datasheet for your convenience),

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up